Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety.
نویسندگان
چکیده
Abbreviations: ACT 5 activated clotting time; APTT 5 activated partial thromboplastin time; AT 5 antithrombin; AT-III 5 antithrombin III; CI 5 confidence interval; DVT 5 deep vein thrombosis; GP 5 glycoprotein; HIT 5 heparininduced thrombocytopenia; INR 5 international normalized ratio; LMWH 5 low-molecular-weight heparin; MI 5 myocardial infarction; NQMI 5 non-Q-wave myocardial infarction; OR 5 odds ratio; PE 5 pulmonary embolism; PF4 5 platelet factor 4; PTCA 5 percutaneous coronary angioplasty; RR 5 relative risk; sc 5 subcutaneous; tPA 5 tissue plasminogen activator; UA 5 unstable angina; UFH 5 unfractionated heparin (CHEST 2001; 119:64S–94S)
منابع مشابه
Preparation, properties and preclinical pharmacokinetics of low molecular weight heparin-modified isoliquiritigenin-loaded solid lipid nanoparticle
Low molecular weight heparin-modified isoliquiritigenin-loaded solid lipid nanoparticle (LMWH-ISL-SLN) was developed for injective application. The morphological observation, particle diameter and zeta potential of LMWH-ISL-SLN were characterized using transmission electron microscopy (TEM) and a Malvern Zetasizer. Its entrapment efficiency (EE) and drug loading (DL) were determined by ultracen...
متن کاملPreparation, properties and preclinical pharmacokinetics of low molecular weight heparin-modified isoliquiritigenin-loaded solid lipid nanoparticle
Low molecular weight heparin-modified isoliquiritigenin-loaded solid lipid nanoparticle (LMWH-ISL-SLN) was developed for injective application. The morphological observation, particle diameter and zeta potential of LMWH-ISL-SLN were characterized using transmission electron microscopy (TEM) and a Malvern Zetasizer. Its entrapment efficiency (EE) and drug loading (DL) were determined by ultracen...
متن کاملAnticoagulants in heart disease: current status and perspectives.
List of abbreviations . . . . . . . . . . . . . . . . . . 2 Preamble: purposes and scope of the task force . . 2 Blood coagulation . . . . . . . . . . . . . . . . . . . . 3 Haemostasis . . . . . . . . . . . . . . . . . . . . . 3 Arterial thrombosis . . . . . . . . . . . . . . . . . 3 Tissue factor . . . . . . . . . . . . . . . . . . . . . 3 Tissue factor pathway inhibitor . . . . . . . . . . 3 ...
متن کاملPercutaneous treatment of a giant right ventricular outflow tract pseudo-aneurysm and severe pulmonary regurgitation.
ary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation 2003;107:238–244. 24. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001;119:64S–94S. 25. Antman EM. The search for replace...
متن کاملDosing of Enoxaparin in Renal Impairment.
OBJECTIVE To review enoxaparin treatment dosing, pharmacokinetics, and clinical outcomes data in patients with renal impairment and to examine the current two-tiered dosing regimen approved by the Food and Drug Administration (FDA). DATA SOURCES A literature search of PubMed (1990-2016) was performed using the search terms low-molecular-weight heparin, unfractionated heparin, bleeding, enoxap...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Chest
دوره 119 1 Suppl شماره
صفحات -
تاریخ انتشار 2001